Optiver Holding
PRLD icon

Optiver Holding’s Prelude Therapeutics PRLD Stock Holding History

Optiver Holding’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21 Sell
4
-16
-80% -$70 ﹤0.01% 2707
2026
Q1 		$68 Hold
20
– – ﹤0.01% 2252
2025
Q4 		$58 Hold
20
– – ﹤0.01% 2393
2025
Q3 		$29 Buy
+20
New +$20 ﹤0.01% 2637

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Optiver Holding's PRLD Position: Q2 2026 in Review

Optiver Holding reduced its Prelude Therapeutics (PRLD) stake by 80% in Q2 2026, selling an estimated $70 and leaving 4 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Optiver Holding first reported a position in PRLD in Q3 2025 and has held it in 4 quarters since. The position peaked at $68 in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Optiver Holding held 4 shares of Prelude Therapeutics worth $21 as of Q2 2026.
  • Optiver Holding sold 16 Prelude Therapeutics shares in Q2 2026, an estimated $70.
  • Prelude Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2707 holding.
  • Optiver Holding first reported a position in Prelude Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Prelude Therapeutics position peaked at $68 in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.